AXL receptor tyrosine kinase, together with its ligand, growth-arrest-specific protein 6 (Gas6), is a new therapeutic target overexpressed in various cancers and significantly associated with tumor proliferation, metastasis, EMT, and acquisition of CSC characteristics (Gay et al., 2017; Zhu et al., 2019). The gene discussed is GAS6; the disease is cancer.